Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-Line BiotechNSE:QLINE -1.12%14 Altman Z2-Score is 4.17 as of Aug. 13, 2026, which is 4% below its 10-year median of 4.33. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 56.55% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Q-Line Biotech has a Altman Z2-Score of 4.17, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Q-Line Biotech's Altman Z2-Score or its related term are showing as below:
NSE:QLINE'
s Altman Z2-Score Range Over the Past 10 Years
Min: 4.17 Med: 4.33 Max: 5.34
Current: 4.17
During the past 3 years, Q-Line Biotech's highest Altman Z2-Score was 5.34. The lowest was 4.17. And the median was 4.33.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Q-Line Biotech Altman Z2-Score Related Terms
Q-Line Biotech Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Altman Z2-Score Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Altman Z2-Score
5.34
4.33
4.17
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Altman Z2-Score
5.34
4.33
4.17
NSE:QLINE vs ABT, SYK, MDT: Altman Z2-Score Comparison
For the Medical Devices subindustry, Q-Line Biotech's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Altman Z2-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Q-Line Biotech's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.1877
+
3.26
*
0.4107
+
6.72
*
0.1262
+
1.05
*
0.7153
=
4.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Q-Line Biotech (NSE:QLINE) has a Altman Z2-Score of 4.17 as of Aug. 13, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Q-Line Biotech and its competitors. This is near median its historical median of 4.33. Over the past decade, Q-Line Biotech's Altman Z2-Score has ranged from 4.17 to 5.34. According to the industry distribution chart, Q-Line Biotech ranks #365 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 43.5%.
Is Q-Line Biotech's Altman Z2-Score too high?
Q-Line Biotech's current Altman Z2-Score of 4.17 is near median its 10-year median of 4.33. Over the past 10 years, this metric has ranged from a low of 4.17 to a high of 5.34. The Medical Devices & Instruments industry median Altman Z2-Score is 3.45. Q-Line Biotech's value of 4.17 is 20.9% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #365 out of 840 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Altman Z2-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #365 out of 840 companies for Altman Z2-Score. This puts Q-Line Biotech in the upper half of its industry. The industry median Altman Z2-Score is 3.45. Q-Line Biotech's value of 4.17 is 20.9% above this benchmark. Historically, Q-Line Biotech's own Altman Z2-Score has ranged from 4.17 to 5.34 over the past decade. While the company's 10-year median is 4.33 vs. the industry median of 3.45, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.45, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Altman Z2-Score of 4.17 is 20.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Altman Z2-Score is 4.17, which is near median its own 10-year median of 4.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Altman Z2-Score of 4.17. The current Altman Z2-Score is 4.17, which is near median its 10-year median of 4.33 and 20.9% above the Medical Devices & Instruments industry median of 3.45. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Altman Z2-Score is 4.17 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score
Get the complete analysis for NSE:QLINE
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 
